Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | June 10, 2025 | June 11, 2025 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-06-10 | Direct | 12,500 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The stock option vests and becomes exercisable on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on June 10, 2026.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBANY MOLECULAR RESEARCH INC
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 1
1 source rowRow 1 · 2017-08-31 · Disposition to issuer · Disposed 11,210 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.77 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-31 · Disposition to issuer · Disposed 6,540 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2027-02-08 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 9,358 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.
PFIZER INC
Report date December 31, 2016 · Filed February 07, 2017
Section 16 reporting ended · disclosed 2017-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,140 |
Reported balance
After 2016-12-21 transaction · row 1
1 source rowRow 1 · 2016-12-21 · Gift · Disposed 2,586 · Balance 110,140 |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 55,216 |
Reported balance
Holding disclosure · report date 2016-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 55,216 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 11, 2025 16:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014693 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $355.20 | $125.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $388.64 | $125.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.50 Strike: $24.60 | $250.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 17:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-24-023148 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 6, 2025. Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001493152-23-019459 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on May 25, 2024. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 16:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001493152-22-027432 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2032-09-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on September 30, 2023. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 17:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001493152-21-018902 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2031-08-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on August 4, 2022. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:34 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001213900-20-017811 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2027-07-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 16:16 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | PurchaseOrdinary Shares | 25,000 | $0.47 | $11,750.00 |
DisclosureSEC source: 0001213900-19-016936 · ownership.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,570 Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 16:39 UTC | Intec Pharma Ltd. NTEC · Entity 146542 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001213900-19-011969 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2026-06-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on June 28, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through June 28, 2022. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:27 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 9,358 | $3.34 Strike: $18.41 | $31,255.72 |
DisclosureSEC source: 0001638599-17-000871 · doc4_4886.xml · derivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,358 shares Expires 2027-02-08 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:27 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,540 | $5.98 Strike: $15.77 | $39,109.20 |
DisclosureSEC source: 0001638599-17-000871 · doc4_4886.xml · derivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,540 shares Expires 2026-02-04 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:27 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerCommon Stock | 11,210 | $21.75 | $243,817.50 |
DisclosureSEC source: 0001638599-17-000871 · doc4_4886.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantOption to Purchase Common Stock · Derivative | 9,358 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001638599-17-000181 · doc4_4515.xml · derivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,358 Underlying: Common Stock · 9,358 shares Expires 2027-02-08 F1 · derivative.exercise_date: Option is exercisable as to 1/3rd of the shares annually on the anniversary date of the grant for each of the next three years. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 3,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000181 · doc4_4515.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,210 Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 22:39 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 241 | $32.48 | $7,827.68 |
DisclosureSEC source: 0001225208-17-000138 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,249 Underlying: Common Stock · 241 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 21, 2016 Filed Feb 7, 2017 23:07 UTC | PFIZER INC PFE · Entity 2863 | GiftCommon Stock | 2,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-002627 · doc5.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,140 Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 01:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 240 | $32.75 | $7,860.00 |
DisclosureSEC source: 0001225208-16-043426 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,007 Underlying: Common Stock · 240 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 16:14 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | PurchaseCommon Stock | 1,518 | $16.46 | $24,986.28 |
DisclosureSEC source: 0001638599-16-001641 · doc4_4367.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,408 Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 23:35 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 244 | $32.14 | $7,842.16 |
DisclosureSEC source: 0001225208-16-042543 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,766 Underlying: Common Stock · 244 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 15:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 244 | $32.23 | $7,864.12 |
DisclosureSEC source: 0001225208-16-041917 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,519 Underlying: Common Stock · 244 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 09, 2016 Filed Nov 11, 2016 00:44 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 10,000 | $33.00 | $330,000.00 |
DisclosureSEC source: 0001225208-16-041471 · doc4.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,087 Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:36 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 65,334 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-16-041196 · doc4.xml · derivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,334 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:36 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 32,545 | $21.03 | $684,421.35 |
DisclosureSEC source: 0001225208-16-041196 · doc4.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| October 31, 2016 Filed Nov 1, 2016 22:32 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 247 | $31.71 | $7,832.37 |
DisclosureSEC source: 0001225208-16-040958 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,626 Underlying: Common Stock · 247 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 12:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 240 | $32.66 | $7,838.40 |
DisclosureSEC source: 0001225208-16-040524 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,363 Underlying: Common Stock · 240 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 23:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 252 | $33.65 | $8,479.80 |
DisclosureSEC source: 0001225208-16-040266 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,107 Underlying: Common Stock · 252 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 232 | $33.87 | $7,857.84 |
DisclosureSEC source: 0001225208-16-040154 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,854 Underlying: Common Stock · 232 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 12:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 230 | $34.14 | $7,852.20 |
DisclosureSEC source: 0001225208-16-039462 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,627 Underlying: Common Stock · 230 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2016 Filed Sep 1, 2016 22:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 225 | $34.80 | $7,830.00 |
DisclosureSEC source: 0001225208-16-038697 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,389 Underlying: Common Stock · 225 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2016 Filed Aug 16, 2016 19:59 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 223 | $35.11 | $7,829.53 |
DisclosureSEC source: 0001225208-16-037940 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,158 Underlying: Common Stock · 223 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 29, 2016 Filed Aug 1, 2016 21:13 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 213 | $36.89 | $7,857.57 |
DisclosureSEC source: 0001225208-16-037261 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,332 Underlying: Common Stock · 213 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2016 Filed Jul 19, 2016 21:13 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 213 | $36.77 | $7,832.01 |
DisclosureSEC source: 0001225208-16-036874 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,121 Underlying: Common Stock · 213 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 07, 2016 Filed Jul 8, 2016 21:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 237 | $35.77 | $8,477.49 |
DisclosureSEC source: 0001225208-16-036669 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,918 Underlying: Common Stock · 237 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2016 Filed Jul 5, 2016 21:29 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 223 | $35.21 | $7,851.83 |
DisclosureSEC source: 0001225208-16-036161 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,687 Underlying: Common Stock · 223 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2016 Filed Jun 16, 2016 22:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 225 | $34.79 | $7,827.75 |
DisclosureSEC source: 0001225208-16-035192 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,467 Underlying: Common Stock · 225 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2016 Filed Jun 3, 2016 00:18 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 226 | $34.70 | $7,842.20 |
DisclosureSEC source: 0001225208-16-034509 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,248 Underlying: Common Stock · 226 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 13, 2016 Filed May 16, 2016 20:42 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 236 | $33.19 | $7,832.84 |
DisclosureSEC source: 0001225208-16-033369 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,069 Underlying: Common Stock · 236 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 09, 2016 Filed May 11, 2016 20:35 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 8,950 | $33.75 | $302,062.50 |
DisclosureSEC source: 0001225208-16-033153 · doc4.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,922 Read SEC document |
| April 29, 2016 Filed May 2, 2016 22:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 240 | $32.71 | $7,850.40 |
DisclosureSEC source: 0001225208-16-032207 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,255 Underlying: Common Stock · 240 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2016 Filed Apr 18, 2016 21:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 241 | $32.50 | $7,832.50 |
DisclosureSEC source: 0001225208-16-031511 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,021 Underlying: Common Stock · 241 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 12, 2016 Filed Apr 14, 2016 01:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 926 | $31.96 | $29,594.96 |
DisclosureSEC source: 0001225208-16-031428 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,790 Underlying: Common Stock · 926 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2016 Filed Apr 4, 2016 17:36 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 258 | $29.64 | $7,647.12 |
DisclosureSEC source: 0001225208-16-030699 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,884 Underlying: Common Stock · 258 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2016 Filed Mar 17, 2016 18:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 4,298 | $29.54 | $126,962.92 |
DisclosureSEC source: 0001225208-16-030010 · doc4.xml · derivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,619 Underlying: Common Stock · 4,298 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2016 Filed Mar 17, 2016 18:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units (AIP) · Derivative | 14,009 | $29.54 | $413,825.86 |
DisclosureSEC source: 0001225208-16-030010 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,749 Underlying: Common Stock · 14,009 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent incentive compensation that has been deferred and will be settled in ten annual installments. F2 · derivative.expiration_date: These units represent incentive compensation that has been deferred and will be settled in ten annual installments. Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 6,905 | $30.23 | $208,738.15 |
DisclosureSEC source: 0001225208-16-028811 · doc4.xml · nonDerivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,693 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 896 | $30.23 | $27,086.08 |
DisclosureSEC source: 0001225208-16-028811 · doc4.xml · nonDerivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,598 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 6,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-028811 · doc4.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,494 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 57,781 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001225208-16-028383 · doc4.xml · derivative · entry 7 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,781 Underlying: Common Stock · 57,781 shares Expires 2023-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.